Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.

IF 7.8 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Therapeutic Advances in Endocrinology and Metabolism Pub Date : 2026-07-16 eCollection Date: 2026-01-01 DOI:10.1177/20420188261463401

Antonia-Therese Kietaibl, Marcus Säemann, Stefan Scherr, Kadriye Aydinkoc-Tuzcu, Peter Fasching, Lisa Frühwald

{"title":"Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.","authors":"Antonia-Therese Kietaibl, Marcus Säemann, Stefan Scherr, Kadriye Aydinkoc-Tuzcu, Peter Fasching, Lisa Frühwald","doi":"10.1177/20420188261463401","DOIUrl":null,"url":null,"abstract":"<p><p>Automated insulin delivery (AID) is the gold standard of treatment for type 1 diabetes mellitus (T1DM). However, little data on the use in people on peritoneal dialysis (PD) exist. To share real-world experience on the use of AID (Medtronic MiniMed 780G SmartGuard and Guardian 4 continuous glucose monitoring system) in a woman living with type 1 diabetes on PD, we report the implementation despite the complex setting of type 1 diabetes with multiple diabetes-associated complications, PD, visual impairment, and a complete language barrier. Glycemic control 14 days before the start of AID on multiple daily injections and 9 months after the conversion is presented. AID might be a safe and promising therapeutic option for individuals with T1DM and end-stage kidney disease requiring PD. Further research is needed to demonstrate both safety and efficacy in this special population, and assessment of patient-reported outcome measures.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261463401"},"PeriodicalIF":7.8000,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376455/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188261463401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Automated insulin delivery (AID) is the gold standard of treatment for type 1 diabetes mellitus (T1DM). However, little data on the use in people on peritoneal dialysis (PD) exist. To share real-world experience on the use of AID (Medtronic MiniMed 780G SmartGuard and Guardian 4 continuous glucose monitoring system) in a woman living with type 1 diabetes on PD, we report the implementation despite the complex setting of type 1 diabetes with multiple diabetes-associated complications, PD, visual impairment, and a complete language barrier. Glycemic control 14 days before the start of AID on multiple daily injections and 9 months after the conversion is presented. AID might be a safe and promising therapeutic option for individuals with T1DM and end-stage kidney disease requiring PD. Further research is needed to demonstrate both safety and efficacy in this special population, and assessment of patient-reported outcome measures.

查看原文本刊更多论文

自动胰岛素输送在1型糖尿病妇女腹膜透析中的应用：一例报告。

自动胰岛素输送（AID）是治疗1型糖尿病（T1DM）的金标准。然而，关于腹膜透析（PD）患者使用的数据很少。为了分享在一名患有1型糖尿病的女性PD患者中使用AID（美敦力MiniMed 780G SmartGuard和Guardian 4连续血糖监测系统）的实际经验，我们报告了在1型糖尿病合并多种糖尿病相关并发症、PD、视力障碍和完全语言障碍的复杂情况下的实施情况。每日多次注射AID前14天及转化后9个月血糖控制情况。对于T1DM和需要PD的终末期肾病患者来说，AID可能是一种安全且有前景的治疗选择。需要进一步的研究来证明在这一特殊人群中的安全性和有效性，并评估患者报告的结果措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Endocrinology and Metabolism Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

7.70

自引率

2.60%

发文量

审稿时长

8 weeks

期刊介绍： Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.